These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34136491)

  • 1. The Biological Function, Mechanism, and Clinical Significance of m6A RNA Modifications in Head and Neck Carcinoma: A Systematic Review.
    Jing FY; Zhou LM; Ning YJ; Wang XJ; Zhu YM
    Front Cell Dev Biol; 2021; 9():683254. PubMed ID: 34136491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
    Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
    Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma.
    Arumugam P; George R; Jayaseelan VP
    Arch Oral Biol; 2021 Feb; 122():105030. PubMed ID: 33383437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
    Paramasivam A; George R; Priyadharsini JV
    Am J Cancer Res; 2021; 11(7):3688-3697. PubMed ID: 34354868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma.
    Zhou X; Han J; Zhen X; Liu Y; Cui Z; Yue Z; Ding L; Xu S
    Front Oncol; 2020; 10():718. PubMed ID: 32547941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
    Chen M; Wong CM
    Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-methyladenine RNA modification and cancer.
    Yang J; Chen J; Fei X; Wang X; Wang K
    Oncol Lett; 2020 Aug; 20(2):1504-1512. PubMed ID: 32724392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of an m6A Reader Gene,
    Deng X; Jiang Q; Liu Z; Chen W
    Front Mol Biosci; 2020; 7():68. PubMed ID: 32391379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The m6A reader protein YTHDC2 is a potential biomarker and associated with immune infiltration in head and neck squamous cell carcinoma.
    Li Y; Zheng JN; Wang EH; Gong CJ; Lan KF; Ding X
    PeerJ; 2020; 8():e10385. PubMed ID: 33304653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential.
    Sun X; Fu S; Yuan X; Pu X; Wang R; Wang X; Lu H
    Cancer Gene Ther; 2023 Sep; 30(9):1209-1214. PubMed ID: 37221404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing.
    Wen T; Li T; Xu Y; Zhang Y; Pan H; Wang Y
    Cell Commun Signal; 2023 Dec; 21(1):355. PubMed ID: 38102645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Characteristics, Prognostic Value, and Immune Characteristics of m
    Geng X; Zhang Y; Zeng Z; Zhu Z; Wang H; Yu W; Li Q
    Front Oncol; 2021; 11():629718. PubMed ID: 33816266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
    Qin S; Mao Y; Wang H; Duan Y; Zhao L
    Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
    Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
    Front Oncol; 2021; 11():642159. PubMed ID: 33816290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of N6-methyladenosine RNA modification in cancer.
    Qu Y; Gao N; Zhang S; Gao L; He B; Wang C; Gong C; Shi Q; Li Z; Yang S; Xiao Y
    MedComm (2020); 2024 Sep; 5(9):e715. PubMed ID: 39252821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.
    Zhang Z; Wei W; Wang H; Dong J
    Front Oncol; 2021; 11():743990. PubMed ID: 34722298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.
    Chen F; Xie X; Chao M; Cao H; Wang L
    Front Immunol; 2022; 13():917153. PubMed ID: 35711459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications.
    Wang D; Zhang Y; Li Q; Zhang A; Xu J; Li Y; Li W; Tang L; Yang F; Meng J
    Biomed Pharmacother; 2023 Nov; 167():115477. PubMed ID: 37696088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Model Related to m6A Predicts the Prognostic Effect of Immune Infiltration on Head and Neck Squamous Cell Carcinoma.
    Deng Y; Li K; Tan F; Liu H
    J Oncol; 2021; 2021():1814266. PubMed ID: 34457003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.